long intergenic non-protein coding RNA 2055Genealiases: []
Q-omics provides the consensus-scored LINC02055 profile across patient tissues and cancer cell-line models. LINC02055 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LINC02055 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, LINC02055 RNA expression shows 5,621 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, COAD, and STAD as cancer lineages where LINC02055 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02055 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02055 survival associations across molecular data types. LINC02055 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02055 RNA expression–survival associations across cancer types. High LINC02055 expression shows unfavorable associations in MESO, KIRP, KICH, LUSC and READ, but favorable associations in LAML. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for LINC02055 RNA expression.
This table summarizes LINC02055 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02055. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02055 shows lower tumor expression in COAD, KIRC, KICH and THCA and higher tumor expression in LIHC and BRCA. The COAD box plot shows higher LINC02055 RNA expression in normal versus tumor tissue (log2 FC = −0.096, t-test p < 0.001).
This table shows molecular features associated with LINC02055 in patient tissues and cancer cell lines. In patient samples, LINC02055 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
